Chapter 20
Other Respiratory Disorders
Pulmonary Hypertension: Classification and Pathogenesis
Pulmonary hypertension, or PH, denotes the resting mean pulmonary arterial pressure of 25 mm Hg or higher.
Pulmonary hypertension can be classified into ...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase inhibitors treat pulmonary arterial hypertension or PAH by inhibiting the activity of the phosphodiesterase enzyme.
Phosphodiesterase 5 ...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelin receptor antagonists or ERAs counteract the effects of endothelins, or ETs, to treat pulmonary arterial hypertension or PAH.
ETs are produced ...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are vital in managing pulmonary arterial hypertension.
They mimic prostaglandin I2 and bind to its receptor, IPR, on ...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors or TKIs and calcium channel blockers or CCBs are used for pulmonary arterial hypertension or PAH treatment.
TKIs like ...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy can enhance the quality of life of patients with pulmonary arterial hypertension or PAH who experience hypoxemia or low oxygen levels. This ...
Cystic Fibrosis: Pathogenesis
Cystic fibrosis, or CF, is an autosomal recessive disorder resulting from mutations in the cystic fibrosis transmembrane conductance regulator or CFTR ...
Cystic Fibrosis: Management
Cystic fibrosis, or CF, is an autosomal genetic disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator or CFTR gene.
CF ...
Copyright © 2025 MyJoVE Corporation. All rights reserved